Clinical Trials Browser

Prostatic Neoplasms × sacituzumab govitecan × 90 days × Clear all

NCT03725761 2026-06-04

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Phase 2 Active not recruiting

31 enrolled 12 charts

Prostatic Neoplasms